Bio/Pharma Industry: Beyond Politics and the Pandemic
Representatives of industry organizations discuss crucial business, regulatory, science-based issues facing the industry.
The bio/pharma industry has demonstrated its R&D capabilities by accelerating development of vaccines and therapeutics to combat COVID-19. At the same time the industry faced intense scrutiny and political pressure. What are the short-, medium-, and long-term implications for bio/pharma development and manufacturing?
Panelists James Mayne, PhD, vice-president, Science & Regulatory Advocacy, PhRMA and Phyllis Arthur, vice-president for infectious diseases and diagnostics policy, Biotechnology Innovation Organization (BIO) shared insights during this Editors’ Series discussion moderated by editors of Pharmaceutical Technology and BioPharm International. The discussion was recorded on Nov. 11, 2020, during the 2020 Bio/Pharma Virtual Congress.
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
